CL2022003046A1 - Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos - Google Patents

Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos

Info

Publication number
CL2022003046A1
CL2022003046A1 CL2022003046A CL2022003046A CL2022003046A1 CL 2022003046 A1 CL2022003046 A1 CL 2022003046A1 CL 2022003046 A CL2022003046 A CL 2022003046A CL 2022003046 A CL2022003046 A CL 2022003046A CL 2022003046 A1 CL2022003046 A1 CL 2022003046A1
Authority
CL
Chile
Prior art keywords
heteroaromatic
chemotherapeutic agents
macrocyclic
macrocyclic ether
compounds
Prior art date
Application number
CL2022003046A
Other languages
English (en)
Inventor
Courtney Horan Joshua
Richard Mente Scot
Efrem Pelish Henry
D Shair Matthew
Tang Xinxing
Tangpeerachaikul Anupong
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of CL2022003046A1 publication Critical patent/CL2022003046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de éter macrocíclico heteroaromático heterocíclico, sales farmacéuticamente aceptables de los compuestos y composiciones farmacéuticas de estos. También se describen métodos para tratar o prevenir el cáncer utilizando compuestos de éter macrocíclico heteroaromático heterocíclico, sales farmacéuticamente aceptables de los compuestos y composiciones farmacéuticas de estos.
CL2022003046A 2020-05-05 2022-11-03 Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos CL2022003046A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088589 2020-05-05
US202063060331P 2020-08-03 2020-08-03
US202063125747P 2020-12-15 2020-12-15

Publications (1)

Publication Number Publication Date
CL2022003046A1 true CL2022003046A1 (es) 2023-10-06

Family

ID=78468373

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003046A CL2022003046A1 (es) 2020-05-05 2022-11-03 Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos

Country Status (12)

Country Link
US (2) US11667649B2 (es)
EP (1) EP4146205A4 (es)
JP (1) JP2023525040A (es)
KR (1) KR20230005987A (es)
AU (1) AU2021268345A1 (es)
BR (1) BR112022022530A2 (es)
CA (1) CA3179702A1 (es)
CL (1) CL2022003046A1 (es)
IL (1) IL297898A (es)
MX (1) MX2022013051A (es)
PE (1) PE20230309A1 (es)
WO (1) WO2021226269A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3179702A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2023179600A1 (zh) * 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
TW202400608A (zh) * 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024074414A1 (en) * 2022-10-06 2024-04-11 Syngenta Crop Protection Ag Herbicidal imidazole compounds
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
ATE335050T1 (de) 2000-12-20 2006-08-15 Kyowa Hakko Chemical Co Ltd Squaryliumverbindungen vom metallkomplex-typ sowie optische aufzeichnungsmedien hergestellt unter verwendung derselben
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EP2325226A1 (en) 2002-10-30 2011-05-25 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
EP1756072A2 (en) 2004-04-27 2007-02-28 Wyeth Purification of progesterone receptor modulators
TW200604137A (en) 2004-04-27 2006-02-01 Wyeth Corp Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls
CN101072780B (zh) 2004-09-20 2010-06-23 詹森药业有限公司 用作类固醇性激素受体调节剂的新的含杂原子的四环衍生物
US7445211B1 (en) 2005-03-11 2008-11-04 Walton Daniel J Wall decoration and game apparatus
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
US20070213526A1 (en) 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7915414B2 (en) 2006-11-24 2011-03-29 Yun Chi Blue-emitting organometallic complexes and their application
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
CN101687865A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 稠合的苯并咪唑和氮杂苯并咪唑的区域选择性金属催化合成
AU2008272693A1 (en) 2007-07-02 2009-01-08 Astrazeneca Ab 3-spiropyrimidinetrione-quinoline derivatives and their use as antibacterial agents
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
JP2009234928A (ja) 2008-03-25 2009-10-15 Kyoto Univ 縮合多環芳香族化合物、およびその製造方法
JP5304010B2 (ja) 2008-04-23 2013-10-02 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
WO2011016582A1 (ja) 2009-08-04 2011-02-10 株式会社トクヤマ クロメン化合物
JP4599469B1 (ja) 2009-08-31 2010-12-15 富士フイルム株式会社 有機電界発光素子用材料及び有機電界発光素子
IN2012DN03217A (es) 2009-09-16 2015-10-23 Cylene Pharmaceuticals Inc
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP2013532691A (ja) 2010-07-30 2013-08-19 ドクター レディズ ラボラトリーズ リミテッド 選択的非対称ヒドロホルミル化のための配位子
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
US9181265B2 (en) 2010-12-22 2015-11-10 Universite Catholique De Louvain Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents
FR2969611B1 (fr) 2010-12-28 2013-02-08 Sanofi Aventis Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
HUE030393T2 (en) 2010-12-28 2017-05-29 Sanofi Sa New pyrimidine derivatives, a process for their preparation, and their pharmaceutical use as inhibitors of AKT (PKB) phosphorylation
JP5828846B2 (ja) 2011-01-27 2015-12-09 株式会社トクヤマ クロメン化合物
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
CN102977150B (zh) 2011-09-06 2016-07-06 郑建鸿 含有碳烯配位基的过渡金属错合物结构及其在发光材料的应用
DK2822953T5 (en) * 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
KR20140032823A (ko) 2012-09-07 2014-03-17 롬엔드하스전자재료코리아유한회사 유기 전계 발광 소자
US9502667B2 (en) 2013-01-24 2016-11-22 Idemitsu Kosan Co., Ltd. Organic electroluminescence
WO2014138912A1 (en) 2013-03-13 2014-09-18 Queen's University At Kingston Luminescent compounds and methods of using same
CA2916605C (en) 2013-06-28 2018-04-24 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
KR102100929B1 (ko) 2013-09-04 2020-04-14 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
KR102167048B1 (ko) 2013-12-03 2020-10-19 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
ES2902835T3 (es) 2014-01-09 2022-03-30 Hadasit Med Res Service Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
KR102191992B1 (ko) 2014-01-22 2020-12-17 삼성디스플레이 주식회사 유기 발광 소자
KR102253441B1 (ko) 2014-03-10 2021-05-20 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
KR101793335B1 (ko) 2014-09-30 2017-11-02 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
US20160140491A1 (en) 2014-11-17 2016-05-19 Gregory Forgatch System and method for integrating intermediary and end-user online retail experiences
US9887372B2 (en) 2015-06-11 2018-02-06 Samsung Display Co., Ltd. Amine-based compound and organic light-emitting device including the same
WO2017023902A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
BR112018009550A2 (pt) 2015-11-13 2018-11-06 Mavalon Therapeutics Ltd derivados de 1,4-benzodiazepinona tricíclica substituída como moduladores alostéricos de receptores de glutamato metabotrópico de grupo ii
CN112920201A (zh) 2016-03-03 2021-06-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN106243096B (zh) 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
JP6798851B2 (ja) 2016-10-14 2020-12-09 株式会社トクヤマ クロメン化合物、及び該クロメン化合物を含む硬化性組成物
CN109528717B (zh) 2017-09-21 2021-08-17 中国科学院分子细胞科学卓越创新中心 治疗或预防肥胖或其相关疾病的化合物及其应用
US20210283261A1 (en) 2017-12-05 2021-09-16 Icahn School Of Medicine At Mount Sinai Compositions and Methods for Treating ALK-Mediated Cancer
WO2019120263A1 (zh) 2017-12-21 2019-06-27 广州华睿光电材料有限公司 有机混合物及其在有机电子器件中的应用
TW201932472A (zh) * 2018-01-30 2019-08-16 大陸商上海吉倍生物技術有限公司 具有大環分子結構的化合物及其用途
KR102233636B1 (ko) 2018-02-21 2021-03-30 주식회사 엘지화학 화합물 및 이를 포함하는 유기 발광 소자
KR102192368B1 (ko) 2018-02-28 2020-12-17 주식회사 엘지화학 유기 발광 소자
CN110357905B (zh) 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN108912175A (zh) 2018-06-05 2018-11-30 长春海谱润斯科技有限公司 一种金属铱配合物及其有机发光器件
EP3827003A1 (en) 2018-07-26 2021-06-02 Enterome Process for preparing mannose derivatives
US10593889B1 (en) 2018-09-26 2020-03-17 Idemitsu Kosan Co., Ltd. Compound and organic electroluminescence device
US20220409731A1 (en) 2018-09-27 2022-12-29 Dana-Farber Cancer Institute, Inc. Degraders that target alk and therapeutic uses thereof
CN109912433B (zh) 2019-03-07 2022-04-08 石家庄诚志永华显示材料有限公司 化合物、有机电致发光材料、有机电致发光器件、电子装置
KR20200111577A (ko) 2019-03-19 2020-09-29 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
EP3844166B1 (en) 2019-05-14 2023-07-12 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
WO2021025371A1 (ko) 2019-08-02 2021-02-11 덕산네오룩스 주식회사 유기전기소자
CN112321604A (zh) 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
GB201913756D0 (en) 2019-09-24 2019-11-06 Chromatwist Ltd Contrast agent
CN112812128B (zh) 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
WO2021125791A1 (ko) 2019-12-16 2021-06-24 주식회사 아이센스 C-n 리간드를 갖는 신규 전이금속 전자전달 착체 및 이를 이용한 전기화학적 바이오센서
TW202136246A (zh) 2019-12-19 2021-10-01 德商麥克專利有限公司 電子裝置用化合物
CN113121607B (zh) 2019-12-31 2023-07-04 马鞍山南大高新技术研究院有限公司 一种主配体含喹啉/喹唑啉的红光铱配合物与应用
CN111362967B (zh) 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CA3179702A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN115362155B (zh) 2020-07-22 2024-06-18 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
CN111808147B (zh) 2020-07-28 2023-04-18 奥来德(上海)光电材料科技有限公司 一种有机磷光材料及其制备方法和电致发光器件
CN113105440B (zh) 2021-04-15 2022-10-04 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物及其制备方法和应用

Also Published As

Publication number Publication date
US11667649B2 (en) 2023-06-06
PE20230309A1 (es) 2023-02-14
US20230076627A1 (en) 2023-03-09
WO2021226269A1 (en) 2021-11-11
AU2021268345A1 (en) 2022-11-10
JP2023525040A (ja) 2023-06-14
EP4146205A1 (en) 2023-03-15
EP4146205A4 (en) 2024-05-29
MX2022013051A (es) 2023-01-24
BR112022022530A2 (pt) 2023-02-23
KR20230005987A (ko) 2023-01-10
CA3179702A1 (en) 2021-11-11
IL297898A (en) 2023-01-01
US20220098212A1 (en) 2022-03-31
US20220340586A9 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
CL2022003046A1 (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos
CL2022003045A1 (es) Quimioterápicos de éter macrocíclico heteroaromático solicitudes relacionadas
ECSP22046699A (es) Inhibidores de kras g12c
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
CL2021002995A1 (es) (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CY1125145T1 (el) Αναστολεις cd73
PE20210163A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
WO2018013867A8 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
EP3489232A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MX2021010321A (es) Compuestos macrociclicos.
EA201991700A1 (ru) Селективные ингибиторы jak1
CL2023003020A1 (es) Heterociclos con sustitución amino para tratar cánceres con mutaciones de egfr
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
CU20190095A7 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias